News | Heart Valve Technology | October 10, 2016

University Hospital Zurich Heart Team First to Perform Tricuspid Valve Repair with Cardioband

Device has traditionally been used for mitral valve repairs

Cardioband, first tricuspid valve repair, University Hospital Zurich, Francesco Maisano

October 10, 2016 — Francesco Maisano, clinic director at the University Hospital Zurich, recently led a team of cardiac surgeons and cardiologists in for the first time repairing a leaky tricuspid valve using a new catheter technology.

Maisano, who is also director of the Clinic for Cardiovascular Surgery at USZ, co-director of the University Heart Center and professor at the University of Zurich, began using the Cardioband in Switzerland for repair of the mitral valve. Now he and his team have succeeded in an application at a leaky tricuspid a 75-year-old patient. The patient is doing well. 

The device has been used previously as a patient-friendly method of repairing a leaking mitral valve in the left heart. It is the minimally invasive alternative to open-heart surgery. Maisano was instrumental in the development of Cardioband, which can be gathered with the help of the leaky valve ring and contracted. For this, the band is placed using a catheter around the valve ring (annulus), and is fixed there by small screws and contracted with a wire, so that the flap closes again tightly.

The tricuspid valve separates the right atrium from the right chamber of the heart. A tricuspid regurgitation, i.e. an insufficient performance of the door, can cause serious symptoms. The backflow of blood into the ventricle and in the veins occur and can cause elevated pressure. This can result in problems in the legs and in the abdomen and liver damage. Also, atrial fibrillation may be associated with the consequences of tricuspid regurgitation. The current treatment of insufficiency of the tricuspid valve consisted of a surgical open-heart surgery using a heart-lung machine. 

Maisano explained the advantages of the new Cardioband method: "Since the insufficiency of this heart valve is often created as the result of mitral valve disease, open-heart surgery is often risky surgery. The use of the Cardioband minimally invasive therapy without the use of cardiopulmonary bypass protects the patient and reduces the risk.”

Watch the VIDEO "Transcatheter Tricuspid Valve Repair and Replacement Technologies," and discussion with Rebecca Hahn, M.D.

For more information: www.valtechcardio.com

Related Content

Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Overlay Init